Antitumor Activity of Poloxamer-188 Solution (Myotive) after Oral and Intravenous Administration in Female BALB/c Mice.

We studied the effectiveness of poloxamer-188 solution (Myotive) administered orally and intravenously at a dose of 48 mg/kg to female BALB/c mice before and after inoculation of colon carcinoma. After oral and intravenous administration of the poloxamer, active tumor necrosis and body weight loss for this reason were observed; a decrease in the tumor volume and normalization of the differential blood cell count and hematological parameters were also seen. Thus, poloxamer-188 is a promising antitumor agent presumably affecting the modified lipid bilayer of tumor cells.